This is a routine executive compensation update with no new operational or financial catalysts. Monitor the upcoming AGM for shareholder vote on termination benefits and any further updates on the Phase 3 MSA trial for ATH434.
Price Chart
Executive Summary
Alterity Therapeutics filed a 6-K disclosing changes to CEO Dr. David Stamler's remuneration package, effective October 15, 2026. The revised package includes a base salary of US$525,000 per annum, a short-term incentive of up to 100% of base salary, and enhanced severance and change-of-control benefits. The company intends to seek shareholder approval for termination benefits at its upcoming annual general meeting.
Key Facts
- CEO Dr. David Stamler's base salary set at US$525,000 per annum
- Short-term incentive up to 100% of annualized base salary
- Change-of-control provision accelerates 100% of unvested equity awards
- Severance includes 100% of annual base salary plus 12 months medical coverage
- Shareholder approval to be sought for termination benefits at upcoming AGM
Financial Impact
No material financial impact; CEO base salary of US$525,000 is disclosed but no new capital or operational figures provided.
Risk Factors
- No new clinical or financial data disclosed
- Company faces going concern risk as noted in prior 20-F filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001437749-26-033045 |
| Document: athe20261021_6k.htm | 0001437749-26-033045 |
| Document: 0001437749-26-033045-index-headers.html | 0001437749-26-033045 |
| Document: 0001437749-26-033045-index.html | 0001437749-26-033045 |
| Document: 0001437749-26-033045.txt | 0001437749-26-033045 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 6-K | $2.09 | awaiting T+60 | — | $2.08 (+0.48%) |
Oct 23, 2026 4d ago | 6-K | $2.09 | awaiting T+60 | — | $2.08 (−0.48%) |
Oct 23, 2026 4d ago | 6-K | $2.09 | awaiting T+60 | — | $2.08 (−0.48%) |
Oct 21, 2026 6d ago | 6-K | $2.39 | awaiting T+60 | — | $2.08 (−12.97%) |
Oct 21, 2026 6d ago | 6-K | $2.39 | awaiting T+60 | — | $2.08 (−12.97%) |
Oct 19, 2026 8d ago | 6-K | $2.43 | awaiting T+60 | — | $2.08 (−14.40%) |
Oct 9, 2026 18d ago | 6-K | $3.12 | awaiting T+60 | — | $2.08 (−33.33%) |
Oct 5, 2026 22d ago | Press Release | $3.22 | awaiting T+60 | — | $2.08 (−35.40%) |
Oct 5, 2026 22d ago | 6-K | $3.22 | awaiting T+60 | — | $2.08 (−35.40%) |
Sep 25, 2026 4w ago | 6-K | $3.67 | awaiting T+60 | — | $2.08 (−43.32%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers